Looking to meet patent buyers?
Showcase your patents here for free.
Buyers can easily search and purchase patents in their desired technology fields.
Korea Patent Mall ensures transaction security and transparency
with the industry's lowest commission rates.
.avif)
.avif)
This technology features the Lactobacillus fermentum MSK 408 strain, newly isolated from kimchi and deposited as KCTC18855P, as well as food and pharmaceutical compositions for preventing or treating epilepsy that utilize this strain or its cultures and ferments as an active ingredient.
Epilepsy is a common neurological disorder affecting 0.5–2% of the global population, yet existing anticonvulsants like phenytoin, valproate, and carbamazepine cause side effects such as gastrointestinal irritation and dizziness. The high-fat, low-carbohydrate ketogenic diet used for drug-resistant patients also presents challenges, as it often leads to significant gut-related side effects like nausea, diarrhea, and constipation, making it difficult to maintain.
This technology enables the MSK 408 strain to reduce brain glucose metabolism and blood cholesterol, inhibit the production of the inflammatory cytokine TNF-α, and regulate blood-brain barrier permeability. It also modulates the gut microbiome by decreasing Bacteroidetes while increasing Firmicutes and Desulfobacterota. Furthermore, it alleviates seizure symptoms by increasing the expression of GABA receptors (GABAA1, GABAB1b) and the glutamate transporter GLT-1, and can be formulated for co-administration with a ketogenic diet. It can be applied to adjunctive therapies for pediatric refractory epilepsy, probiotics for use alongside ketogenic diets, and neurological health supplements, offering a new non-pharmacological management tool that reduces seizure frequency via the gut microbiome while mitigating the gastrointestinal side effects of ketogenic diets.
This invention was developed with support from the Ministry of Education for research on the protective effects of synbiotics on epilepsy and neurons.
This technology provides pharmaceutical and food compositions for the prevention and treatment of macular degeneration, containing Compound K—the final intestinal metabolite of ginseng saponin—and the eye health ingredient lutein in a weight ratio of 1:5 to 1:50. Compound K serves to mitigate the side effects associated with lutein use.
Macular degeneration, along with cataracts and glaucoma, is a leading cause of blindness. Dry macular degeneration, which accounts for about 90% of cases, is often overlooked in its early stages as it is asymptomatic or mistaken for presbyopia. While lutein is taken for prevention, long-term high-dose intake can paradoxically cause retinal cell death and accelerate macular degeneration, creating a need for a solution to prevent these effects.
This technology combines Compound K—obtained via chromatography of ginseng extract or commercial sources—with lutein to slow or prevent the cell death and accelerated macular degeneration caused by high-concentration, long-term lutein administration, preferably at a 1:5 to 1:10 ratio. It can be formulated into tablets, capsules, or drinks. Applicable to lutein supplement reformulation, ginseng-based eye health products, and early-stage dry macular degeneration treatments, it allows long-term users to consume lutein safely without fear of retinal damage.
This invention was developed with support from the Ministry of Science and ICT for research on the therapeutic effects of the endogenous metabolite kynurenic acid on non-alcoholic fatty liver disease through the amelioration of endoplasmic reticulum stress.
This technology involves mixing soy sauce and rice bran in a 7:3 to 6:4 (v/w) ratio, adding 1–4 mg of PLP (pyridoxal-5'-phosphate) per 100g of the mixture, and creating anaerobic conditions to rapidly increase the gamma-aminobutyric acid (GABA) content in the soy sauce.
GABA is a functional ingredient known for its calming, stress-relieving, and blood pressure-lowering effects. However, natural plant sources often lack sufficient levels to provide physiological benefits, leading to the development of GABA-enriched products like green tea, rice germ, and germinated brown rice. Methods for increasing GABA in soy sauce have rarely been reported, and there has been a need for new materials and processes beyond existing functional soy sauce technologies that rely on medicinal herbs or mushroom mycelia.
This technology utilizes the glutamate decarboxylase in rice bran to convert the abundant glutamic acid in soy sauce into GABA, while supplementing with PLP—a coenzyme for the enzyme—to accelerate the reaction. Anaerobic treatment is performed at 30–50℃ for 2–24 hours. By pre-spraying rice bran with water, soy sauce, protein hydrolysates, or pH-adjusted ionized water to reach 20–60% moisture, and then adding PLP under anaerobic storage, one can prepare rice bran with pre-enriched GABA. This method is applicable to acid-hydrolyzed, brewed, and enzymatically hydrolyzed soy sauces. It can be used to produce premium functional soy sauce, low-sodium seasonings for blood pressure management, and GABA-fortified sauces and dressings, allowing for the upcycling of rice bran—a milling byproduct—to impart GABA functionality to soy sauce in about a day without long-term fermentation.
This technology involves the CaAPIK1 protein (SEQ ID NO: 1), a newly identified MAP3 kinase that interacts with CaAIPP1 in chili peppers, the gene encoding it, and a recombinant vector containing said gene. It provides a composition for enhancing drought stress resistance in plants, as well as a method for increasing resistance by overexpressing this gene in plants and the resulting transgenic plants.
Drought hinders normal plant growth, leading to reduced yields. As desertification progresses, the need for crops that can withstand water scarcity is growing. However, the complete signaling pathway—from ABA recognition by PYR/PYL/RCAR receptors to the phosphorylation proteins that trigger stomatal closure and stress gene expression—remains unclear, limiting the availability of regulatory genes for improving drought tolerance.
This technology identifies that CaAPIK1 pairs with CaAIPP1 to act as a positive regulator of ABA-mediated stomatal closure. By transforming plants with the chili-derived gene (SEQ ID NO: 2) to overexpress the protein, transpiration loss is suppressed under water-deficit conditions. The resulting transgenic plants are also covered by the scope of this technology. Applicable to breeding drought-tolerant chili varieties for greenhouses and open fields, developing water-saving crops, and creating seeds for export to arid regions, it provides a new genetic target—the CaAIPP1-linked phosphorylation pathway—expanding options for multi-trait breeding in combination with other drought-resistance genes.
This invention was developed with support from the Rural Development Administration's project to develop breeding materials for disease and disaster resistance through the functional characterization of stress-related genes in chili peppers.
This technology involves the MAP3 kinase CaADIK1 (SEQ ID NO: 1), identified as a protein interacting with CaADIP1 in the Nokkwang pepper cultivar, the gene encoding it, a composition for enhancing drought stress resistance containing a recombinant vector with said gene as an active ingredient, and a method for overexpressing this gene in plants via transformation.
As global warming and desertification exacerbate water shortages, drought is hindering crop growth and significantly reducing grain yields. While plants respond to drought by closing stomata via abscisic acid (ABA) signaling, the downstream pathways following ABA receptors remain incompletely understood, limiting the genetic resources available for developing drought-tolerant crops.
This technology leverages the role of CaADIK1 as a positive regulator of ABA signaling that enhances ABA-mediated stomatal closure, reducing water loss in transgenic plants overexpressing the pepper-derived gene (SEQ ID NO: 2). The scope of the claims covers compositions for enhancing drought resistance in the form of proteins, genes, or recombinant vectors. Applicable to breeding field peppers and solanaceous vegetables, developing drought-tolerant crops for regions with irregular rainfall, and creating plants for greening arid areas, this technology utilizes the ADIP1-linked signaling axis to produce crops that remain resilient even with reduced irrigation.
This invention was developed with support from the Rural Development Administration's project to develop breeding materials for disease and disaster resistance through the functional characterization of stress-related genes in chili peppers.
This technology utilizes mastic gum, a resin from the Mediterranean mastic tree, as an active ingredient in pharmaceutical compositions and health supplements for the prevention and treatment of influenza A virus infections. The composition inhibits infection by blocking the stage where the virus enters host cells.
Current treatments like neuraminidase inhibitors (e.g., oseltamivir) and M2 ion channel inhibitors (e.g., amantadine, rimantadine) target viral replication. However, frequent antigenic mutations have led to an increase in drug-resistant viruses. Furthermore, these treatments require oral or intravenous administration, must be taken within 48 hours of symptom onset, and are associated with side effects like nausea and headaches, creating a need for safe, natural alternatives.
By inhibiting the phosphorylation of the MAPK signaling pathway activated during viral infection, this technology blocks the virus from entering cells entirely. Because its mechanism differs from existing drugs that target replication enzymes, it remains effective against resistant strains. Designed for direct nasal administration, it acts rapidly against influenza A-related conditions such as the flu, pharyngitis, bronchitis, pneumonia, and sepsis. It can be applied to nasal spray flu preventatives, adjunctive therapies for Tamiflu-resistant patients, and respiratory health supplements, enabling the creation of natural antiviral products that block infection at the nasal mucosa, the virus's primary entry point.
